Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

Long Islanders suffering from sleep apnea inundated the sleep center at St. Charles Hospital in Port Jefferson with phone ...

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

Novo, valued at $650 billion in June last year, has shed over two-thirds of its value since. Its latest market cap is around ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...